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 This issue of Advance 
features several areas of 
clinical research occurring 
at UT Medical Center. 
Clinical trials offer many 
benefits to all supporters.  
They offer the patient 
hope through treatment 
opportunities that are 
not readily available by 
providing the patients 
access to the novel therapies and offer the 
physician scientists with more treatment options 
and the ability to expand their experience in 
the academic research arena.  Clinical trials 
also offer the institution with yet another 
opportunity to expand its influence and build 
upon its image in geographic s an academic 
institution. Finally, clinical trials offer the 
potential of a revenue stream to defray the cost 
of some health care services and other in- house 
initiated research. Other clinical research efforts, 
such as the work being done on NIH or SBIR 
grants will significantly impact patient care in 
the future. This issue of Advance introduces 
our newly appointed Radiology Chair, Dr. 
Laura Findeiss, MD., FSIR.  She brings diverse 
medical experience to further integrate with the 
Interventional Radiology and clinical research 
efforts both in the Graduate School of Medicine 
and UTMC.  The Department of Medicine has 
several physicians working on three industry 
sponsored clinical trials that are all featured 
in this issue, as well as, a clinically-relevant 
imaging compound that was recently presented 
at the annual meeting of the Society of Nuclear 
Medicine (SNM), where it received significant 
media attention. Jonathan Wall, Ph.D. and 
Michael Karlstad, Ph.D. have both received large 
federal grants to support their current research 
efforts. All of these clinical research efforts at 
UTMCK truly highlight our goal to advance 
research from lab to life.
Paul  J. Ottaviano, M.S.,M.B.A.
Director of Clinical Trials Research Operations
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 Laura Findeiss, M.D., FSIR, a radiologist with 
a diverse professional background that includes 
training in surgery at the UT Graduate School 
of Medicine as well as practicing emergency 
medicine in rural Tennessee, has been appointed 
Chair of Radiology for the UT Graduate School 
of Medicine as of August 1, 2013. Dr. Findeiss is 
a noted vascular and interventional radiologist, 
coming from the University of California Irvine 
Medical Center where she was Division Chief of 
Vascular and Interventional Radiology and Co-
Director of UC Irvine’s Ablative Oncology Center.
 Dr. Findeiss received her medical degree from 
the University of Pittsburgh School of Medicine 
in 1997 followed by two years of General 
Surgery Residency at the UT Graduate School 
of Medicine. She completed her Diagnostic 
Radiology Residency at Virginia Mason Medical 
Center in Seattle, Washington, in 2004, followed 
by a fellowship in Vascular and Interventional 
Radiology at the University of Washington 
Medical Center. 
 As chair, Dr. Findeiss said she plans to use her 
diverse medical experience to further integrate 
Radiology with multidisciplinary teams at The 
University of Tennessee Medical Center. She said, 
“My goal is to determine how we can best support 
the institution and the exciting work the clinics 
are doing here. Radiology is an important part of 
the healing component of our mission, and we 
work with a lot of referring physicians. I hope  
to use Radiology as a hub so that diverse medical 
professionals work together to support  
patient care.”
 Dr. Findeiss lectures nationally on a range of 
Vascular and Endovascular topics, image-guided 
treatment of vascular anomalies, and minimally 
invasive cancer interventions, including tumor 
ablation. She holds national leadership roles as a 
member of the Executive Council of the Society 
of Interventional Radiology, the SIR Foundation 
Board of Directors, and the Leadership 
Committee of the American Heart Association’s 
Cardiovascular Radiology and Intervention 
Council.
 Besides certifications in Diagnostic Radiology 
and Vascular and Interventional Radiology, Dr. 
Findeiss is certified by the American Board of 
Vascular Medicine in Endovascular Medicine 
and is a Registered Physician in Vascular 
Interpretation. She has been honored as a Fellow 
in the Society of Interventional Radiology (FSIR), 
as well as obtaining Fellow status in the American 
Heart Association. 
 Dr. Findeiss’s personal research interests are 
peripheral arterial disease/vascular disease and 
in this area limb perfusion/revascularization for 
critical limb ischemia.  She has an interest in tissue 
perfusion imaging, and in ways to non-invasively 
predict response of the critically ischemic or 
ulcerated limb to revascularization therapies.  
She has experience and interest in clinical trials 
related to peripheral interventions and response of 
tumors to directed therapy, specifically, response 
to hepatocellular carcinoma to the spectrum of 
liver directed therapies available.  Dr. Findeiss is 
particularly interested in the role of post-therapy 
tumor hypoxia in angioneogenesis and subsequent 
tumor growth.  In particular, looking at hypoxia 
imaging agents in this regard. 
 As the department chair, Dr. Findeiss’s major 
research goal for the Department of Radiology 
is moving the Molecular Imagining and 
Translational Research Program (MITRP) forward 
within the department as a comprehensive 
research enterprise incorporating basic science, 
translational imaging research, and investigation 
of clinical applications of novel radiotracers in 
collaboration with our UT Centers of Excellence.  
MITRP can offer an integrated platform for bench 
to bedside investigations for researchers within and 
external to the institution, providing support for a 
broad spectrum of research endeavors.  With the 
internationally recognized basic science program, 
advanced animal imaging facility, and best in class 
clinical PET facility with near-term development 
of the on-site radiopharmacy, the opportunities for 
clinically relevant scientific advances  
are abundant.
My goal is to determine how we 
can best support the institution 
and the exciting work the 
clinicians are doing here.
-Laura Findeiss, M.D.
Why this matters:
Use of novel compounds for rapid definitive clinical 
diagnosis may alter patient management and provide 
patients with improved survival.
Determination of 
Cardiac Amyloid 
Involvement 
 Cardiac amyloidosis is a rare, debilitating and 
inevitably fatal disease with an average survival 
of only 4-9 months, from diagnosis. This disease 
can often manifest with symptoms similar to 
other more common cardiac conditions. Early 
and accurate diagnosis of this condition is key to 
providing the best possible care for these patients. 
Karen Wells, M.D., Alan Solomon, M.D. 
and Jonathan Wall, PhD., in the Department 
of Medicine, began using Florbetapir, a 
commercially available and FDA-approved 
imaging compound for amyloid detection in 
the brains of patients with Alzheimer’s disease, 
in patients with cardiac amyloidosis.  This study 
was designed to examine whether or not this 
compound could effectively image amyloid 
outside of the brain, specifically within the heart. 
Initial results from this study showed promise; 
however, standard clinical PET/CT imaging 
techniques were unable to show a significant 
difference between patients with cardiac 
amyloidosis and healthy subjects. Dr. Osborne, 
along with Alan Stuckey and Shelley Acuff, 
Director of Clinical Research for the MITRP, 
began working with the group on this project 
in 2012 and data acquisition was moved to the 
new state of the art Biograph mCT PET/CT 
scanner installed at the University of Tennessee 
Cancer Institute. Dr. Osborne re-examined the 
image data acquired during the scans and was 
able to show, with a new type of analysis, there 
were substantial differences between amyloid 
patients and healthy subjects. These results 
indicated that using dynamic PET imaging may 
make it possible to identify patients with cardiac 
amyloidosis. 
 The problem with dynamic method of PET 
imaging used to study these patients is that it 
is not performed routinely in the clinic and the 
scan can last more than an hour. This makes it 
extremely difficult to schedule into a busy clinical 
practice. Therefore, Drs. Osborne and Wells 
once again reviewed the data and found that the 
scan time could be reduced to only 20 minutes. 
Further analysis showed that a comparison of 
the heart image between 0-5 minutes with that 
at 15-20 minutes could be used to differentiate 
amyloid patients from the healthy test subjects. 
Specifically, the ratio of the Standard Uptake 
Values (SUVs) in the heart provided the 
information to accurately demonstrate cardiac 
amyloidosis using Florbetapir. 
 This study provided preliminary support 
for assessing cardiac amyloidosis using a new 
clinically-relevant method using an FDA-
approved amyloid imaging compound that was 
easily accessible to clinicians worldwide. The 
method may yield a sensitive imaging test for the 
detection and diagnosis of cardiac amyloidosis. 
This work was presented at the annual meeting 
of the Society of Nuclear Medicine (SNM) in 
Vancouver where it received significant media 
attention garnering an Aunt Minne press release 
as well as headlining the daily SmartBrief sent to 
all members of the SNM.
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     ngoing research to find a 
treatment for cystic fibrosis may 
finally pay off. Bruce Ludwig, 
M.D., Medical Director, Adult 
Cystic Fibrosis Program and the 
clinical trial team are partnering 
with Vertex Pharmaceuticals, Inc. 
to study the underlying mechanism 
of the gene that causes cystic 
fibrosis and its protein product. 
 Cystic Fibrosis is the most 
common fatal genetic disorder of 
Caucasians, affecting about 30,000 
people in the US. It is a genetic 
defect in a protein that impacts 
the transport of chloride, sodium 
and water in all ducts of the body. 
This can cause bronchiectasis 
with chronic and recurrent lung 
infections, often with resistant 
bacteria. Patients also suffer from 
malnutrition, diabetes, liver 
disease, respiratory issues and 
sometimes death.  Most current 
medications are directed to treat 
symptoms of the disease, but now 
there is a drug approved to treat 
the root cause of the disease. 
Vertex Pharmaceuticals 
sponsors cystic 
fibrosis trial
 This trial studies the Vertex drug, Kalydeco, 
combined with Lumacaftor in patients with 
cystic fibrosis. The pairing should improve 
transportation to the membrane and improve 
lung function. If proven to work, the outcome 
would benefit at least 50% of patients with cystic 
fibrosis who carry two copies of the DeltaF508 
mutation. The Food and Drug Administration 
called the collaboration of the two drugs, 
“breakthrough therapy designation,” for its effort 
to speed the development of potential treatments 
for life-threatening diseases or conditions.  
 “These patients would not be able to receive this 
type of medication if it were not for this clinical 
trial,” said Ludwig. 
 Ludwig and his team expect to see significantly 
improved lung function in patients and 
improved weight control in the short term. 
He hopes the long term effects will translate to 
improved survival rates, reduced infections and 
hospitalizations and eventually turn cystic fibrosis 
into a much more controllable disease. 
 “Being able to continue to participate in trials 
like these give them hope for their future,” added 
Ludwig. “Hope that one day there will be a cure 
for the disease that challenges their daily lives.”
O
Why this matters:
This minimally invasive technique may be able to 
provide improved quality of life to people who suffer 
from severe emphysema.
Why this matters:
A significant number of chronic diabetic wounds 
do not heal after a year of treatment with current 
technologies. This application aims to develop an 
Atmospheric Plasma Applicator for treatment of 
chronic wounds. The research team is working to 
design a commercial prototype that is capable of 
inactivating microorganisms, including, biofilm to 
improve wound healing without causing damage to 
surrounding tissues.
Research team:  Alex Nelson, Eric Karlstad, Michael Karlstad, Ph.D., Emily Paulus
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 When medical therapy is no longer effective 
for patients with advanced emphysema, doctors 
often have to consider interventions such as lung 
volume reduction surgery. This procedure removes 
the most severely damaged and over-inflated areas 
of the lung, allowing the healthier lung tissue to 
expand.  It is a major surgery and many of the 
people who need it are too frail to tolerate it.  
 Paul Branca, M.D., James Shamiyeh, M.D., 
and Michael McCormack, M.D., are working 
on the EMPROVE trial, which is testing a new, 
minimally invasive way to provide lung volume 
reduction for patients without undergoing  
surgery. Using a bronchoscope, a small, umbrella-
shaped, one-way valve is placed in the airways 
leading to the damaged lung.  The valves allow air 
and secretions to come out of the target lobe when 
the patient exhales but prevent air from reentering 
on inhalation.  The damaged part of the lung 
deflates, allowing the healthier portion to expand. 
 The University of Tennessee Medical Center is 
one of fewer than 20 centers in the country, and 
the only center in Tennessee participating in this 
trial.  The trial is now open and recruiting patients 
with severe emphysema who have daily symptoms. 
Patients must have completed pulmonary 
rehabilitation and must have quit smoking for at 
least four months. Participants will be randomized 
to either valve treatment or to a control group.  
They will be closely monitored for six months, 
then at yearly intervals. To find out more,  
please contact the trial coordinator,  
Lauren Davis, at 865-305-7975.
EMPROVE Clinical Trial: 
Evaluating a Non-surgical 
Treatment Approach to 
Severe Emphysema
 Five to seven million Americans are treated 
annually for chronic wounds that arise from 
diabetes, lower extremity arterial disease, lower 
extremity venous disease and edema, pressure 
ulcers, and traumatic injuries, including burns. 
Michael Karlstad, Ph.D., Department of Surgery 
is a principal investigator on a two-year Small 
Business Innovation Research (SBIR) grant 
awarded to Advanced Plasma Products, Inc., 
from the National Institute of General Medical 
Sciences, which aims to develop a prototype 
for treating these wounds.  Karlstad’s two other 
principal investigators include Kimberly Kelly-
Wintenberg, the general manager and director 
of business development from Advanced Plasma 
Products, Inc. (Knoxville, TN) and Garth James, 
Ph.D., a professor in the University of Montana 
Center for Biofilm Engineering will help in this 
endeavor.  
 This phase II multi-principal investigator 
NIH proposal will allow the investigative team 
to pursue development of an atmospheric plasma 
applicator to treat chronic wounds in diabetes.  
Karlstad’s research team will be responsible 
for experiments designed to demonstrate the 
therapeutic potential of atmospheric plasma 
to improve wound healing by the removal of 
microorganisms from the biofilm of chronic 
diabetic wounds.  Karlstad’s collaborators on 
the small business grant include Patricia Coan, 
D.V.M., Ph.D, Jason Collier, Ph.D., and Deidra 
Mountain, Ph.D.  Brian Daley, M.D. and Jeffery 
Hecht , M.D., from the Department of Surgery, 
will serve as clinical consultants.  
Development of an Atmospheric Plasma 
Applicator to Treat Chronic Wounds
IN BRIEF »»»»»»
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 Pneumonia is one of the most common 
infections among critically ill patients in 
intensive care units nationwide. A bigger concern 
to physicians is that the infection is sometimes 
resistant to multiple antibiotics, making it 
difficult to treat. 
 Rajiv Dhand, M.D., Paul Branca, M.D., 
Carol Ellis, M.D., Tina Dudney, M.D., Michael 
McCormack, M.D., and Department of 
Medicine fellows at the University of Tennessee 
Medical Center are studying ways to combat 
pneumonia by using inhaled antibiotics in 
ventilated patients.  The doctors 
conducting this industry sponsored 
trial believe the levels achieved by 
inhaling the antibiotics should be able 
to effectively and safely treat infections 
with multi-drug resistant bacteria. 
   “We are fortunate not to currently 
have this problem in our hospital,” 
said Rajiv Dhand, M.D. “However, 
in many other hospitals, physicians 
are finding it increasingly difficult to 
effectively treat infections caused by 
such resistant organisms and alternative methods 
of treatment are urgently needed.”
 These physicians believe inhaling the 
antibiotics, in addition to usual standard of care, 
could provide an additional means of combating 
such serious, and even fatal, infections.
 Inhaled therapies allow several advantages for 
patients. Lower doses, with higher concentrations 
of the drug, will enhance antibacterial activity 
against resistant pathogens.  Furthermore, 
patients will experience better tolerability due to 
lower prescribed doses. 
 Another possible benefit is that if aerosolized 
medication is able to be delivered to the lungs 
with more efficiency than is currently possible, 
then it may prove useful as adjunctive therapy for 
patients in the future. 
 This multi-center study will prospectively 
determine the role of inhaled antibiotics in 
addition to usual standard of care antibiotics for 
treatment of pneumonia in ventilated patients. 
UTMC is one of more than 150 sites worldwide 
participating in the trial. 
The Department of Medicine  
participates in clinical trial
IN BRIEF »»»»»»
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 Radio and TV ads suggest that testosterone can 
cure depression, improve mood and 
sexual performance, even boost 
energy and melt away extra 
pounds. Hormone experts 
say those looking for a 
quick fix are turning 
to Rejuvenation 
Clinics (RC) to treat 
hypogonadism, or low 
testosterone. 
 While testosterone 
replacement therapy 
is proven to improve 
sex drive, erectile 
function, muscle mass 
and bone density, 
there is little known 
about these drugs’ 
effect on men’s fertility. 
 Jared Moss, M.D., 
chief resident, Dept. of 
Urology, studied the 
impact of rejuvenation 
hormones on sperm 
count. “Rejuvenation 
Clinics are becoming 
more popular and men are having 
children at later ages than ever 
before,” said Moss. “Testosterone 
reduces sperm counts and may 
compromise fertility.”
 The normal range of 
testosterone is 300 to 1,000 ng/dL 
(nanograms per deciliter) of blood. 
After age 30, men typically have a 
slow decline of testosterone.  
Low testosterone, or Low 
T, is generally indicated at a 
testosterone level under 300, 
paired with symptoms such as low 
sex drive, excessive fatigue, depression and 
weight gain.  
 The data from his study 
also suggests that there is a link 
between prostate cancer and 
testosterone. “Testosterone 
does not cause prostate 
cancer, but it may exacerbate 
it if it is already there,” said 
Moss. 
 Findings from Dr. Moss’ 
study were featured in The 
Washington Post. For the 
full article please see http://
www.washingtonpost.com/
national/health-science/
everything-you-need-to-know-
about-low-testosterone-
but-were-afraid-to-
ask/2013/06/24/3bdeb2d6-
d764-11e2-a016-
92547bf094cc_story.html
Doctors Investigate Impact of  
Testosterone Replacement Therapy
Why this matters:
Many of the men, as well as physicians who 
prescribe testosterone, are not aware that 
testosterone replacement therapy impacts  
fertility negatively.
Why this matters:
These patients are considered to have a very 
serious condition with a fairly high mortality rate. 
Therefore, we are looking for ways to reduce the 
morbidity and mortality rate of these patients. 
IN BRIEF »»»»»»
Your Chance to Advance
 The people at the UT Graduate School of Medicine would be happy to discuss our 
research programs and how your support can help advance healthcare.  For information 
about philanthropic giving to the UT Graduate School of Medicine Office of Research, 
please contact the development office at 865-305-6611 or development@utmck.edu. 
 If you would like more information about any research programs described in this 
issue of Advance, please contact the UT Graduate School of Medicine’s Research 
Coordinator, Kristen Bass, at 865-305-9749 or visit online:  
http://gsm.utmck.edu/research/main.cfm.                                                 
      Thank you.
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AlAn Solomon, m.D., retireS
Alan Solomon, M.D.  
retired from the 
University of Tennessee 
after  47 years. During 
his tenure at UT, 
Dr. Solomon served 
as a Professor in the 
Department of Medicine 
and as the Director of 
the Human Immunology 
and Cancer Research 
Program.  He held 
National Institutes of Health grants for four 
decades and maintained a very successful clinical 
practice. He has given most of his adult years as a 
physician and medical researcher to improve the 
quality of life of his patients.  
reni leSlie, irB ASSociAte  
Director, retireS
After 32 years 
of service to the 
University of 
Tennessee, Reni Leslie 
retired at the end of 
2013. For 18 of those 
32 years, Reni served 
the Graduate School of 
Medicine as Assistant 
Director of the Internal 
Review Board. 
GAwrySiAk’S DiSSertAtion puBliSheD
Former Cole Neuroscience Center PhD student, 
Michael Gawrysiak, had his dissertation, titled 
“Pragmatic Psychodynamic Psychotherapy for 
a Patient with Depression and Breast Cancer: 
Functional MRI Evaluation of Treatment 
Effects”, published in the American Journal of 
Psychotherapy. 
utmc AppointS clinicAl  
triAl Director
University of Tennessee Medical Center 
appointed Paul Ottaviano as the Clinical 
Trial Director. Mr. Ottaviano has over 35 
years of executive leadership, entrepreneurial, 
research, and teaching experience in the 
healthcare industry. In addition he has taught 
undergraduate and graduate college level courses 
from time to time as an adjunct professor, served 
on the boards of colleges, presidential advisory 
committees, and lead efforts to commercialize 
intellectual property at Emory School of 
Medicine. He will be joined by Janet Parkey, 
CPA and several current site coordinators and 
regulatory document staff in various clinical 
departments at the University of Tennessee 
Medical Center (UTMC). Together they will 
develop the operation and attract sponsors of 
drugs, biologics, and devices to work with the 
newly created division and its physician and 
medical staff supporters at UTMC.
roGer cArroll, ph.D., retireS
Roger Carroll, Ph.D. has 
retired after 29 years of 
service to the University 
of Tennessee. Dr. 
Carroll’s research efforts 
predominately focused 
on the area of peri-
operative coagulation 
testing and management, 
with particular focus on 
assessment of platelet 
function in a clinically relevant manner. He was 
a valued faculty member of the Department of 
Anesthesia who will be greatly missed.
News»
 Jonathan Wall, Ph.D., professor in the 
Department of Medicine and director of the 
Preclinical and Diagnostic Molecular Imaging 
Laboratory, received a four-year grant from 
the National Institute of Diabetes and 
Digestive and Kidney Diseases, a subsidiary 
of the National Institutes of Health to study 
“Preclinical Diagnostic Imaging of Amyloid.”
 It is well known that patients with Alzheimer’s 
and other disorders, such as type 2 diabetes, 
develop amyloid, a substance composed of sticky 
protein fibers and sugar molecules that builds 
up in the brain or other organs in the body. 
Doctors do not know whether this material 
causes the diseases, or whether the diseases lead 
to amyloid formation. However, in less common 
diseases, such as light chain amyloidosis, a rare 
but devastating illness caused by the aggregation 
of antibody-related light chain 
proteins in organs such as the 
heart, liver, kidneys and spleen, 
there is no doubt that amyloid 
presence in the organs is the 
cause of the disease.
   There is an urgent need 
to image amyloid in order 
to accurately diagnose and 
determine the stage of the 
disease and monitor the 
therapies used to treat patients. 
However, in the United States 
there are no clinically available 
methods to image amyloid in 
patients, except in those with 
Alzheimer’s disease. Many 
patients travel to Europe for a scan, where the 
technology is available. With the help of his 
team, including Steven Kennel, PhD; Alan 
Stuckey, BA, CNMT; Tina Richey, MS; Sallie 
Macy, BA; Craig Wooliver, MLT; Emily Martin, 
BS; and Angela Williams, MS, Dr. Wall has 
developed a series of new imaging agents aimed 
at advancing the diagnosis and treatment of 
patients with amyloid-related diseases. Dr. Wall’s 
new imaging agent is a peptide, a protein he has 
named p5. In preclinical testing, radioactive p5 
has been shown to bind to amyloid in the brain 
and other organs, making the amyloid visible 
through positron emission tomography (PET) 
imaging and other techniques. It is expected 
that with appropriate modifications, p5 may 
eventually be used in the clinical setting to image 
amyloid throughout the body.
Preclinical Diagnostic Imaging of Amyloid
Why this matters:
In the U.S., our ability to detect amyloid deposits 
is limited,” Dr. Wall said. “We’ve made amazing 
progress, but we need to move faster. The peptide 
p5 is the next generation of amyloid-imaging 
agents, and it holds much promise for helping 
people with amyloid-related diseases”.
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